Why the study?
Does Klkb1 deficiency or Mas receptor modulation alter thrombosis times in mice?
Does Klkb1 deficiency or Mas receptor modulation alter thrombosis times in mice?
Klkb1 deficiency protects against thrombosis through a novel pathway involving increased Mas receptor, prostacyclin, Sirt1, and KLF4, leading to reduced vascular tissue factor.
No takes yet. Share an insight, caveat, or question.
Should not alter clinical antithrombotic practice; hypothesis-generating for Mas-Sirt1 pathway in human thrombosis research.
Stavrou et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: